financetom
Business
financetom
/
Business
/
Update: Market Chatter: Kenvue CEO Sough to Prevent RFK Jr. From Citing Tylenol as Potential Autism Cause
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Update: Market Chatter: Kenvue CEO Sough to Prevent RFK Jr. From Citing Tylenol as Potential Autism Cause
Sep 15, 2025 2:50 AM

05:35 AM EDT, 09/15/2025 (MT Newswires) -- (Updates with response from the Department of Health and Human Services in the fifth and sixth paragraphs)

Kenvue's ( KVUE ) interim chief executive Kirk Perry had a private meeting with Robert F Kennedy Jr. to dissuade the Secretary of Health and Human Services from citing Tylenol as a potential cause for autism, The Wall Street Journal reported Friday, citing a person familiar with the matter.

The Journal reported last week that Kennedy plans to point at acetaminophen, the active ingredient in Tylenol, taken by pregnant women, as a potential cause of autism in their children, among other reasons.

The report is expected from the Department of Health and Human Services later this month, the report said.

"Our position remains the same: in evaluating available science, we continue to believe that taking acetaminophen does not cause autism, and global health regulators, independent public health organizations, and medical professionals agree," Kenvue ( KVUE ) said, according to the WSJ.

A spokesperson for the Department of Health and Human Services said they are using "gold standard science" to investigate the rise in autism cases in the country.

"HHS officials regularly meet with stakeholders to get their perspective about our agenda to Make America Healthy Again. Any claims regarding this or any other specific meeting, however, are nothing more than speculation unless officially discussed by HHS," they said.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Deals of the day-Mergers and acquisitions
Deals of the day-Mergers and acquisitions
Sep 28, 2024
Sept 27 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 0930 GMT on Friday: ** Australia's REA Group ( RPGRF ), owned by Rupert Murdoch controlled-News Corp ( NWSA ), bumped up its takeover bid for Rightmove ( RTMVF ) to 6.2 billion pounds ($8.29 billion) after the UK firm rejected three of its previous offers....
Bristol-Myers Squibb Says Schizophrenia Drug Received FDA Approval
Bristol-Myers Squibb Says Schizophrenia Drug Received FDA Approval
Sep 28, 2024
04:28 AM EDT, 09/27/2024 (MT Newswires) -- Bristol-Myers Squibb Company ( BMY ) said Thursday the US Food and Drug Administration has approved its oral medication Cobenfy for the treatment of schizophrenia in adults. The drug, also known as xanomeline and trospium chloride, was approved based on phase 3 clinical trials during which it met its primary endpoint of statistically...
Update: Market Chatter: Chevron Agrees Hess CEO Will Not Join Board Under US FTC Agreement
Update: Market Chatter: Chevron Agrees Hess CEO Will Not Join Board Under US FTC Agreement
Sep 28, 2024
05:37 AM EDT, 09/27/2024 (MT Newswires) -- (Updates with response from Chevron ( CVX ) and the FTC in the third paragraph.) Chevron ( CVX ) has agreed that Hess (HES) Chief Executive John Hess will not join its board as part of a US Federal Trade Commission deal, Bloomberg reported Thursday, citing people familiar with the matter. The condition...
EnVenno Medical Prices $15 Million Public Offering
EnVenno Medical Prices $15 Million Public Offering
Sep 28, 2024
04:04 AM EDT, 09/27/2024 (MT Newswires) -- EnVVeno Medical ( NVNO ) said Thursday it has priced a public offering of about 4.3 million common shares or pre-funded warrants at $3.50 per share gross expected gross proceeds of about $15 million. The underwriter has been granted a 30-day option to purchase up to 642,857 additional shares. Net proceeds from the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved